IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing.
IntelliCyt – cell and bead-based screening solutions
IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. Its flagship product, the iQue Screener combines the sensitive, proven detection technology of flow cytometry with a patented sample processing technology, running a 96-well microplate in 3 minutes. The iQue Screener is part of a complete solution of application-specific reagent kits and software.
MultiCyt cellular assays have been specifically designed for simultaneously monitoring multiple cell health endpoints, many using no-wash, low-volume 384- and 1536-well protocols. Cell health screens can monitor a variety of endpoints including proliferation, membrane integrity, apoptosis and genotoxicity. QBeads PlexScreen is a panel of antibody-coated beads for secreted proteins, enables high throughput screens of 1–30 analytes, with no wash steps and a price compatible with high throughput screening. The IntelliCyt technology suite will be of interest to research groups interested in augmenting their phenotypic screening capabilities in suspension cells, primary cells, and heterogeneous cell cultures.
Founded in 2006 by life science entrepreneurs and leading scientists, IntelliCyt Corporation was the first to commercialize a true high throughput screening platform for suspension cells that addresses urgent unmet research needs. Management Team is composed by Terry Dunlay, Thomas Duensing, Janette Phi and Dennis Hynson. Board of Directors is composed by Raymond Radosevich, Bo Saxberg, Michael Schafer, Jack Ball, Dan Kidle, Tim Petersen and Terry Dunlay.
More about IntelliCyt : www.intellicyt.com